- [PRESSWIRE] Belgium – 18.09.23 — AbolerIS Pharma (“AbolerIS”), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne Capital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead program in clinical trials and explore its effectiveness in additional autoimmune diseases.
- [PRESSWIRE] Vienna, Austria – 02.05.2003 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 25, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented preclinical data supporting the development of a computationally-derived amyloid-beta (Aβ) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 24, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company’s lead candidate for AD, PMN310. The data were presented in poster presentations on April 23 at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston, MA.
- PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies Greater selectivity of PMN310 for toxic oligomers indicates a potentially differentiated profile and supports further development
- [PRESSWIRE] New York, NY (USA) and Santiago de Compostela (Spain), 8 January 2023. EVQLV Inc. and Libera Bio S.L. have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent high unmet medical needs.
- [PRESSWIRE] New York, NY (USA) and Santiago de Compostela (Spain), 8 January 2023. EVQLV Inc. and Libera Bio S.L. have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent high unmet medical needs.
- [PRESSWIRE] Nairobi – November 9, 2022 — The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.
- [PRESSWIRE] Nairobi – November 9, 2022 — The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.
- [PRESSWIRE] Austria – 04.07.22 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA —April 28, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.
- [PRESSWIRE] LUBBOCK, TX — April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — February 3, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board (SAB).
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE – Mass. — January 27, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Dr. Cheryl Wellington to its scientific advisory board (SAB).
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 18, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses. Schizophrenia is a clinical term for a severely disabling neuropsychiatric disease that disrupts employment, families and communities, and likely has heterogenous biological origins.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 7, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on Jan. 11, 2022 from 8 AM to 9 AM PST.
- [PRESSWIRE] Austria – 10.12.21 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).
- [PRESSWIRE] Japan – 21 October, 2021 — Post COVID-19 syndrome, a developing world-wide problem may be alleviated by Japan originated medical device “suisonia”.
- [PRESSWIRE] Vienna — 17th August 2021 – CEBINA GmbH, Central European Biotech Incubator and Accelerator today announces the publication of the first results of a Phase 2 efficacy clinical trial sponsored jointly with its partner URSAPHARM Arzneimittel GmbH demonstrating that a nasal spray containing the active ingredient azelastine was effective in accelerating the reduction of the viral load in SARS-CoV-2 positive patients. Azelastine has been marketed in an identical composition by URSAPHARM for many years and is used as an antiallergic.
- Carbon Engineering and BeZero Carbon join forces to offer a new retail option for customers seeking to address their carbon footprint through Direct Air Capture technology. BeZero’s Carbon Rating Framework gives customers an additional tool to assess the quality of available solutions, with Direct Air Capture the only AAA+ top-rated solution.
- Frodeno is renowned as one of the greatest triathletes of his generation. The Olympic gold medalist will use the Supersapiens system to effectively manage his fueling strategy to continue in his pursuit of earning another Ironman World Championship title.
- [PRESSWIRE] Austria – 04 May, 2021 — CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.
- [PRESSWIRE] Madrid, Spain – 25 January, 2021 — An innovative new technology from Necenti Labs offers 96% accuracy for COVID-19 detection before infection with deep data to give companies and individuals the power of knowledge to battle lockdown.
- [PRESSWIRE] SANTA ANA, January 26, 2021 — Airionex, the leading global provider of bi-polar ionization air and surface purification technology, announced today that it has hired Françoise Parker as Senior Vice President of Sales and Marketing. Françoise will report to CEO Jukka Matikka, and will be responsible for sales team leadership, accelerating Airionex revenue throughout North America, the development and management of key channels, and overseeing the company’s marketing strategy.
- The disruptive NordShield® technology can offer masses durable antiviral and antibacterial protection in everyday life, while being ecological and the antimicrobial effect lasting min. 30 washes…
- [PRESSWIRE] Denmark – 14 December, 2020 — Many challenges are associated with the conventional eye drop bottle. The global ophthalmic industry has long pushed for a way to better deliver medication to the eye. Now, the Danish-based MedTech start-up, EYE-GO, has the solution that can improve the lives of millions of people globally suffering from dry eyes and other chronic eye conditions. Leading ophthalmologists and frontrunning international players in the industry have already named it “a true game-changer in eye care”. The Danish state participated in the latest funding round.
- [PRESSWIRE] Austria – 19.11.20 — Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company, today announces the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines8040689).
- [PRESSWIRE] CA, US – 18 September, 2020 — Airionex announced today the results of new independent testing. Varionix® active bipolar ionization air cleaning technology from Airionex has been verified to be effective for disinfecting coronavirus from the air. The virus was completely eliminated within minutes.
- [PRESSWIRE] US – 19 September, 2020 – B Medical Systems, a leading European medical refrigeration and global vaccine cold chain manufacturer, is pleased to announce the official opening of its new 10,000 sq ft sales office and warehouse in Noblesville, Indiana. With over 40 years of experience in the medical refrigeration and vaccine cold chain market, the company offers a full line of medical-grade refrigerators, freezers, ultra-low temperature freezers, and transport devices designed for the safe storage and transport of biological materials, critical samples, blood, and vaccines.
- [PRESSWIRE] Vienna – 30th June 2020 — Eveliqure Biotechnologies today announces that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total investment provided by Arax. This is complemented by further private investment from Baobá and a Swiss based family office, and totals around €0.5M.
